OncoMatch/Clinical Trials/NCT07328854
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
Is NCT07328854 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Cisplatin-based induction chemotherapy and Full course of PD-1 monoclonal antibody for nasopharyngeal carcinoma.
Treatment: Cisplatin-based induction chemotherapy · Full course of PD-1 monoclonal antibody — This study aims to explore the efficacy and adverse events of reduced-dose radiotherapy (40.2Gy) versus conventional-dose radiotherapy (49.2Gy) to low-risk target volume for chemosensitive intermediate-stage nasopharyngeal carcinoma patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage T1-3N2M0, T3N0-1M0, STAGE II (AJCC/UICC TNM 9th edition)
Staged according to the 9th edition of the AJCC/UICC TNM classification as T1-3N2M0 or T3N0-1M0 (Stage II)
Demographics
Prior therapy
Must have received: induction chemotherapy plus immunotherapy (gemcitabine, docetaxel, albumin-bound paclitaxel, paclitaxel, cisplatin) — induction
Imaging evaluation of treatment response after three cycles of GPP/TPP induction chemotherapy plus immunotherapy: CR or PR
Cannot have received: radiotherapy or surgery to local/regional lesions (excluding diagnostic surgery)
Patients whose local/regional lesions have undergone radiotherapy or surgery (excluding diagnostic surgery)
Lab requirements
Blood counts
wbc ≥ 4 × 10⁹/l, plt ≥ 100 × 10⁹/l, hgb ≥ 90 g/l
Kidney function
creatinine clearance ≥ 60 ml/min or creatinine ≤ 1.5 times the upper limit of normal
Liver function
total bilirubin, ast, alt ≤ 2.0 times the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07328854 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiotherapy or surgery to local/regional lesions (excluding diagnostic surgery) disqualifies patients from enrollment.
What disease stage is eligible?
Stage T1-3N2M0 or T3N0-1M0 or STAGE II is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages